Accelerated development of malaria monoclonal antibodies.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 36260982.
- Also identified by DOI 10.1016/j.xcrm.2022.100786 and PMC identifier 9589116.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
L9LS, a potent and safe antimalarial monoclonal antibody, demonstrated 88% protective efficacy against infection in a phase 1 trial in healthy adults.<sup>1</sup> These promising results are the first of many to usher in a potential new era of malaria prevention.
Medical subject headings
- Antibodies, Monoclonal
- Antimalarials
- Malaria